statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara Therapeutics, Inc. (NASDAQ: CDTX) resulting from...

CDTX LOSS ALERT: ROSEN, A LEADING LAW FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation CDTX

- Multispecific CD73/PD-1 DFC demonstrates improved tumor reduction compared to PD-1 monotherapy in nonclinical study - CCR5-targeting DFC demonstrates potent efficacy in colorectal cancer...

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024

Cidara Therapeutics, Inc. (NASDAQ:CDTX  Get Free Report) insider Leslie Tari sold 21,029 shares of the businesss stock in a transaction that occurred on Monday, March 11th. The shares...

Insider Selling: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Insider Sells 21,029 Shares of Stock

Cidara Therapeutics, Inc. (NASDAQ:CDTX  Get Free Report) CFO Preetam Shah sold 18,931 shares of the businesss stock in a transaction that occurred on Monday, March 11th. The stock was...

Insider Selling: Cidara Therapeutics, Inc. (NASDAQ:CDTX) CFO Sells 18,931 Shares of Stock

Abstracts to include preclinical data on several drug-Fc conjugate (DFC) candidates including multispecific CD73/PD-1 DFC, CCR5 targeting DFC and CBO421 (CD73 targeting DFC)SAN DIEGO, March 06, 2024...

Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024

Approval triggered by positive results from ReSTORE Phase III clinical trialPayment will advance Cidara's Cloudbreak platform for the development of drug-Fc conjugates (DFCs) SAN DIEGO, Feb...

Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO

Novozymes A/S (OTCMKTS:NVZMY  Get Free Report) and Cidara Therapeutics (NASDAQ:CDTX  Get Free Report) are both basic materials companies, but which is the better stock? We will compare...

Comparing Novozymes A/S (OTCMKTS:NVZMY) & Cidara Therapeutics (NASDAQ:CDTX)

Raymond James Financial Services Advisors Inc. increased its stake in shares of Cidara Therapeutics, Inc. (NASDAQ:CDTX  Free Report) by 25.2% in the third quarter, according to the company in...

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Stake Lifted by Raymond James Financial Services Advisors Inc.

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

MHRA approves Cidara Therapeutics' Rezzayo for invasive candidiasis in adults

The UK MHRA approval follows approvals by the U.S. FDA and the European CommissionCidara is entitled to receive a milestone payment of approximately $2.8 million from Mundipharma SAN DIEGO, Jan...

Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Volume	21,376.00
52-Wk High	$29.60
52-Wk Low	$10.00

Period	Estimated	Reported	Surprise	Result
Q1'24	-$2.39	--	--	N/A
Q4'23	-$0.04	-$0.80	-1900.00%	MISSED
Q3'23	-$0.15	-$0.09	40.00%	BEAT
Q2'23	-$0.13	-$0.14	-7.69%	MISSED
Q1'23	-$0.04	$0.03	181.82%	BEAT

CDTX Cidara Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals